⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Official Title: A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Study ID: NCT02935153

Study Description

Brief Summary: The overall purpose of this study is to explore the therapeutic effect of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Malignant B-cell Derived Leukemia and Lymphoma.

Detailed Description: CD22 is a type I transmembrane protein expressed on most mature B lymphocyte in the B cell malignancies,and plays a significant role in signal transduction pathways.Despite of the fact that CD19-targeted CAR-T can re-induce remissions for many patients with relapsed and refractory B cell malignancies, a part of those patients will relapse with CD19-negative malignancies. To explore a rescue for those with CD19-negative B cell malignancies, we design and conduct this trial to test the safety and effectiveness of CD22-targeted CAR-T.

Eligibility

Minimum Age: 14 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China

Contact Details

Name: Cheng Qian, MD, PhD

Affiliation: Biotherapy Center of Southwest Hospital

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: